introduction
The primary aim of anticancer therapies is to improve patient survival. However, the toxicities of these therapies and their impact on patient's quality of life are equally important. The precise knowledge of treatment-related adverse events (AEs), as well as the resulting impact on quality of life often influences physicians' choice of an anticancer regimen for an individual patient. The main source of information about treatment-related AEs is from the publications of randomized, controlled trials (RCTs) [1] . To optimize the reporting of RCTs data, the Consolidated Standards of Reporting Trials (CONSORT) guidelines provide a checklist of essential items that should always be reported [2] . In 2004, the CONSORT guidelines were extended to include 10 recommendations for toxicity reporting [3] . However, toxicity reporting in RCTs remains suboptimal in both oncology and nononcology trials [4] [5] [6] [7] [8] .
Although a description of all emergent toxicities is important and relevant, determination of overall drug toxicity and tolerability are usually based on a few key AEs such as grade 3/4 AEs, AEs leading to death (grade 5 AEs), or those resulting in study withdrawal or dose reduction. Accurate reporting of these data is therefore essential. Hence, in this study, we systematically reviewed the reporting of such key AEs in all oncology RCTs reports published between 2007 and 2011. RCTs characteristics associated with a better reporting of key AEs were also investigated. Members of the European Organization for Research and Treatment of Cancer (EORTC) network were invited to an online survey regarding their expectations on key AEs reporting in phase III reports. The results of this survey were compared with the current status of key AEs reporting.
methods study selection
We identified using Medline via PubMed (http://www.pubmed.gov) all English publications of RCTs assessing systemic anticancer therapies published between January 2007 and December 2011. We selected 10 Exclusion criteria were: pediatric studies; treatment with radiotherapy or surgery only; phase I, II, or IV trials; supportive care, palliative care, or prevention trials; meta-analyses, overviews, or publications using pooled data from two or more trials; and secondary reports of previously published trials [9] [10] [11] .
data extraction and quality assessment All manuscripts were reviewed independently by two investigators (DM and JP) for eligibility. If eligible, data were independently extracted by both investigators. Discrepancies were resolved by consensus. For the purposes of data extraction, grade 3/4 AEs as defined by recognized toxicity grading scales such as the Common Terminology Criteria for Adverse Events scales were assessed in all manuscripts. Moreover, the reporting of frequencies of grade 5 AEs, AEs leading to study withdrawal, and AEs leading to dose reductions was also assessed. For all-grade AEs and grade 3/4 AEs, the investigators noted whether a reporting threshold was explicitly stated (i.e. the frequency below which an AE would not be explicitly reported in the study).
The description of the nature of key AEs (i.e. febrile neutropenia, congestive heart failure …) was also collected. A key AE outcome was considered to be described when both frequency and nature of the key AEs were reported in the manuscript. For example, grade 5 AEs were adequately reported when the exact number of grade 5 AEs was reported as well as the nature of AEs leading to death.
analysis
We explored whether key AEs reporting was influenced by: funding characteristics (solely or partially sponsored by industry); geographic regions; type of investigational therapy; year of publication; journal impact factor; the result of primary outcomes ( positive or negative study); the treatment line (adjuvant or metastatic); and tumor type. Univariate and multivariable logistic regression analyses were used to identify factors associated with an adequate description of key AEs outcomes (especially grade 5 AEs, AEs leading to study withdrawal, and AEs leading to dose reductions).
questionnaire to EORTC members regarding AE reporting
The EORTC membership was invited to an online survey of 11 questions regarding their expectations on AEs reporting. This survey was approved by the EORTC executives (Denis Lacombe) and validated by the EORTC board in July 2013. The respondents were not aware of the results of our review at the time of the questionnaire. A follow-up reminder was sent if no response had been received after 6 months.
results

characteristics of selected RCTs
From the 739 trials initially screened, a total of 325 RCTs were included in this analysis (Figure 1 ). Characteristics of selected RCTs are presented in Table 1 . The number of RCTs published in the 10 selected journals was broadly stable between 2007 and 2011. The most commonly enrolled tumor types were lung cancers (n = 72, 22% of RCTs); breast cancers (n = 74, 23%), and colon/rectum cancers (n = 48, 15%). Most commonly, the description of all-grade and grade 3/4 AE reporting in phase III trials manuscripts
Among the 325 RCT reports, the majority (96%) provided data about grade 3/4 AEs, and 61% reported data about all-grade AEs. The reporting thresholds were explicitly stated in 60 manuscripts (18%) for all-grades AEs and in 56 manuscripts (17%) for grade 3/4 AEs. The median values of reporting percentage thresholds for all-grade and grade 3/4 AEs were 10% (range 0%-25%) and 3% (range 0%-20%), respectively. In nine manuscripts (3%), the reporting thresholds were different for all-grade AEs and grade 3/4 AEs. Moreover, in 88 RCTs (27%), authors clearly specified that the reported AEs were at least possibly related to the trials drugs while in 37 RCTs (11%), the reported AEs were not necessarily related to the trials drugs. Finally, in 200 RCTs (62%), it was not clear whether or not the reported AEs were those related to the trials drugs.
reporting of grade 5 AEs, AEs leading to study withdrawal or dose reduction in phase III trials manuscripts
An adequate description of grade 5 AEs, AEs resulting in study withdrawal or dose reduction was infrequent (Table 2 ). Only 50% of the manuscripts adequately described the frequency and nature of grade 5 AEs encountered in the study. Another 23% reported the frequency of grade 5 AEs but did not provide information on nature of AEs leading to death, while 27% provided no information on grade 5 AEs. A multivariate analysis revealed that the conduction of a trial in Europe was an independent factor associated with a less frequent reporting of grade 5 AEs frequency (P = 0.004) ( Table 3 ). There was no factor predicting adequate description of grade 5 AEs nature (supplementary Table S1 , available at Annals of Oncology online). Frequency and nature of AEs leading to study withdrawal were adequately reported in only 19% of manuscripts (Table 2) . Another 55% reported the frequency of these AEs but without an adequate description of their natures. A total of 26% did not report on AEs leading to study withdrawal at all. A higher reporting frequency of AEs leading to withdrawal was independently associated with industrial funding (P = 0.0051) and with breast or urological cancer types (P = 0.0061, supplementary Table S2 , available at Annals of Oncology online). There was no factor predicting an adequate description of AEs leading to drug discontinuation nature (supplementary Table S3 , available at Annals of Oncology online).
Only 10% of the manuscripts adequately described AEs leading to dose reductions (Table 2) . Another 26% reported the frequency of AEs leading to dose reduction but without any description on their nature. Finally, 61% of the manuscripts did not report the number of dose reduction due to AEs. The dose reduction frequencies were independently more frequently reported in studies testing a cytotoxic chemotherapy (P = 0.0006) (supplementary Table S4 , available at Annals of Oncology online). A study testing a cytotoxic chemotherapy (P = 0.028) was also predictive of an Table S5 , available at Annals of Oncology online). Lastly, we thought it was instructive to extract the rates of key AEs occurring in the control arms of studies where patients received placebo or best supportive care (BSC). In RCTs using placebo or BSC as a control (n = 47 on 325 RCTs), grade 3/4 AEs "related to placebo or BSC" occurred in ∼25% of patients. Placebo discontinuation due to an AE occurred in ∼3% of patients. These observations have no clinical relevance because information that stems from reporting of AEs for placebo and BSC arms is not very useful for clinicians, who are unlikely to consider such AEs as treatment-related toxicity. Similarly, the vast majority of EORTC investigators who answered the survey felt that it was important to systematically specify the frequency of grade 5 AEs in each phase III reports (99%) and also to describe the nature of grade 5 AEs (96%). A majority of them also felt that the frequency of AEs leading to study withdrawal should always be reported (98%) and that the nature of these AEs should always be described (86%). Finally, AEs leading to dose reduction frequency and nature should always be reported for 88% and 70% of the responding EORTC members, respectively. Thus, a very substantial gap exists between the expectations of the EORTC members for key AEs reporting and the current status of key AEs reporting (Figure 2 ).
discussion
The reporting of AEs in RCTs offers a unique opportunity to assess and compare the tolerance of treatments. It represents a key source of information for therapeutic decision and also significantly influences new drug development. In the present study, we assessed the reporting of key AEs in oncology phase III reports published between 2007 and 2011. The same database was used to assess the overall adherence of phase III reports to CONSORT recommendations for AEs reporting. Despite the The frequency (in %) of grade 5 should always be reported 208 99 7
The frequency (in %) of AEs leading to study withdrawal should always be reported 207 98 8
The frequency (in %) of AEs leading to dose reduction should always be reported 186 88 9
When they occurred, the types of AEs leading to death should always be described 201 96 10
When they occurred, the types of AEs leading to study withdrawal should always be described 181 86 11
When they occurred, the types of AEs leading to a dose reduction should always be described 148 70 shown that the reporting of toxicity remained suboptimal [8] . In the current study, we found that even key AEs were often underreported. Grade 5 AEs were adequately described in only 50% of reports; AEs leading to study withdrawal in 19% of reports; and AEs leading to dose reduction was provided in 13% of reports. Given these results, the possibility that patient treatment and drug development decisions are made without proper regard to critical toxicities seems probable in many instances. Unfortunately, this is in line with the literature in other medical subspecialties, where problems of a similar or greater magnitude were seen [6] . Our results are even more startling when contrasted with the expectations of clinical researchers in a large clinical research network such as the EORTC. It is clear that a very substantial gap exists between the expectations of the EORTC members for key AEs reporting and the current status of key AEs reporting. The reasons for these remain unclear. The observation that European studies were more likely to under-report some key AEs suggest that differences in regional practice, or perhaps in the prevalence of industry-associated studies, may be relevant.
On the basis of our data, we propose that specific attention should be paid to the reporting of AEs in general but to the key AEs that we have described in particular. The reporting of overall frequencies of grade 3/4 AEs, usually in a dedicated table, was very high in our review and this should clearly be maintained. However, it is common practice only to report grade 3/4 AEs that occur above a certain frequency and reporting all-grade 3/4 AEs, even if uncommon, should be considered as rare toxicities may still be significant or life-threatening. At the very least, we would argue that any key AEs that occur in 5% or more patients should be reported. Also, we think that adequate qualitative description is also vital so allow a proper recognition and appreciation of these toxicities by readers. Although we chose to focus on the quantitative aspects of AE reporting (i.e. grade 3/4 AEs or frequencies of grade 5 AEs, withdrawal frequencies …), it is clear that qualitative aspects of AEs reporting (i.e. the practice of grouping different AEs under a same heading such as cardiac AEs or neurologic AEs) also need to be investigated. Indeed, the reporting of AEs in clinical trials aims mostly at protecting patients who participate in trials whereas assessment of toxicity is a selection of clinically relevant undesirable events.
One limitation to these data is the low response rate (6.3%) despite follow-up reminders. This magnitude of responders was not unexpected and is in line with many similar survey-based studies reported response rates [12, 13] . However, the validity of the conclusions of this survey are strengthened by the fact that we received responses from more than 50% of the institutions affiliated with the EORTC and responses were received from 29 different countries. The responses are likely to be related among investigators working daily in a same center, so we hypothesize the outcomes to our survey are probably a good reflection of what many researchers think. Also, our study focused on 10 journals and on published phase III reports rather than including all journals and all oncology trials. While it is possible that our results may change if we had included all trials in all journals, we think that this is unlikely given that these 10 journals publish the bulk of major oncology RCTs. We also felt that toxicity data in phase III reports are especially relevant as these studies are likely to impact on physician therapeutic strategies.
These findings clearly demonstrate that there is a lot of room for improving the reporting of key AEs in oncology RCTs. Not only is this intuitively important, but also we show an overwhelming number of the EORTC respondents to our survey stated that adequate reporting of such toxicities are imperative. The emergence of new anticancer therapies undoubtedly provides news hope for patient care but inadequate toxicity reporting may undermine their development and result in patient harm. Our data provide a framework of key areas of AE reporting that could be improved. 
